Bifogade filer
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2024-11-19 07:30:04
19.11.2024 07:30:01 CET | Thor Medical ASA | Non-regulatory press releases
Oslo, November 19, 2024: Thor Medical ASA, a leading emerging supplier of
alpha-emitters for next-generation precision cancer treatment, today ships the
first product samples of Thorium-228 alpha-emitters from its newly commissioned
pilot facilities at Herøya. The shipment marks another important milestone in
Thor Medical's journey toward commercial operations.
"Since opening our pilot facilities at Herøya less than two months ago, our
highest priority has been to ensure process and product quality. Targeted cancer
care with alpha-emitters holds the potential to transform cancer treatment
regimes, and this successful first production run marks another significant step
towards commercially viable production of alpha-emitters", says Jasper Kurth,
CEO of Thor Medical.
The first Thorium-228 product samples are today being shipped to an undisclosed
potential customer, one of several potential customers for supply of Thorium-228
from Thor Medical.
The first product shipment follows other recent key de-risking milestones,
including the on-time and on-budget completion of the Herøya pilot facilities in
September, and the signing of a strategic 5-year supply agreement for
Thorium-228 with ARTBIO in October.
On 25 November, Thor Medical hosts a Capital Markets Update in Stockholm,
including presentations from both Thor Medical and ARTBIO.
CONTACTS
* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visitwww.thormedical.no - https://www.thormedical.no.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18327833/5297/Download%20announce
ment%20as%20PDF.pdf